来自MSN1 天
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...
PipelineReview.com4 天
FDA approves Lumakras® (sotorasib) in combination with Vectibix® (panitumumab) for ...
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC ...
조선일보8 天
Johnson & Johnson CEO highlights Lecraza's potential to transform lung cancer treatment
Johnson & Johnson CEO highlights Lecrazas potential to transform lung cancer treatment Johnson & Johnsons leader underscores ...
Taiwan News5 天
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
THE CHOSUNILBO on MSN6 天
South Korea’s FDA-approved Leclaza offers breakthrough in lung cancer survival
South Korea’s first domestically developed anti-cancer drug approved by the U.S. Food and Drug Administration (FDA), has ...
Pharmabiz12 天
US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed ...
US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins: Shanghai Thursday, January 9, 2025, 1 ...